Challenges and Advances in Sepsis Detection
FDA-approved tests like Intellisep and TriVerity demonstrate potential for early sepsis diagnosis
Testing Trends-dtet
Next-Generation Sequencing Vs. Sanger Sequencing: Key Differences
Clinical lab professionals will want to note the pros and cons each technology brings
AI Model Detects Genetic Colorectal Cancer Markers from Routine Tissue Slides
Model links tumor morphology with multiple genetic alterations, offering faster diagnostics
AI: With the Lab Every Step of the Way
Artificial intelligence models have a valuable role to play in each phase of the total testing process.
Profiling Pathogens for Public Health
Genomic epidemiology can provide insights into pathogen transmission and evolution—and facilitate better countermeasures against infectious disease.
Expert Q&A: What’s Next in Next-Generation Sequencing?
Crystal Girod, MSc, of Beckman Coulter Life Sciences discusses recent developments in NGS and their impact on clinical diagnostics.
Seeing Past the AI Hype
Artificial intelligence won’t take your job—but what are the real concerns around healthcare AI and its use?
Which Test? Choosing the Best Approach to Diagnosing Rare Disease
Genomic sequencing is almost twice as likely to yield a diagnostic result, but lags behind panel testing in speed, cost, and concordance.
Pursuing the PFAS Problem
Tackling the challenges of “forever chemicals” in the diagnostics industry.
CDC Calls Continued Rise in Cases of STIs “Alarming”
Health inequities and disrupted STI testing and care during the pandemic continued to contribute to a rise in cases in 2021.
How Could Cheaper Genomic Sequencing Affect the Clinical Testing Industry?
Recently released NGS systems will be helpful to researchers but are unlikely to immediately impact diagnostics, expert says.
Expert Q&A: Recent Trends in the Clinical Lab
G2 Intelligence managing editor Rachel Muenz chats with lab leader Stephanie Whitehead about recent developments affecting clinical labs.
USPSTF Again Declines to Recommend Lipid Screening for Asymptomatic Children
The panel recently said there was still not enough evidence to properly assess the harms and benefits of such screening.
